Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 86 publications
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± Pembrolizumab.
Journal: European urology oncology
Published: March 20, 2026
Prognostic Utility of ctDNA for Trimodality Therapy Outcomes in Muscle Invasive Bladder Cancer.
Journal: Clinical genitourinary cancer
Published: December 17, 2025
EV-103 dose escalation/cohort A: 5-year follow-up of enfortumab vedotin plus pembrolizumab in previously untreated locally advanced/metastatic urothelial carcinoma.
Journal: ESMO open
Published: November 06, 2025
A phase Ib/II, open-label, multicenter, randomized umbrella study evaluating the combination of atezolizumab with sacituzumab govitecan in patients with locally advanced or metastatic urothelial carcinoma and previously treated with a platinum-based treatment regimen (MORPHEUS-Urothelial Carcinoma).
Journal: ESMO open
Published: July 11, 2025
Unmet Potential of Antibody-Drug Conjugates: An Evaluation of the Past, Present, and Future of Antibody-Drug Conjugate Development in Advanced Urothelial Carcinoma.
Journal: American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
Published: February 06, 2025
Clinical and Translational Results from PORTER, a Multicohort Phase I Platform Trial of Combination Immunotherapy in Metastatic Castration-Resistant Prostate Cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: November 19, 2024
Patients Can Administer Mobile Audio Recordings to Increase Knowledge in Advanced Prostate Cancer.
Journal: Cancer medicine
Published: August 16, 2024
Modulating the PPARγ pathway upregulates NECTIN4 and enhances chimeric antigen receptor (CAR) T cell therapy in bladder cancer.
Journal: Nature communications
Published: July 02, 2024
NCCN Guidelines® Insights: Bladder Cancer, Version 3.2024.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: May 16, 2024
HER2 overexpression in urothelial carcinoma with GATA3 and PPARG copy number gains.
Journal: The oncologist
Published: March 08, 2024
Patient-Reported Outcomes in Patients With Advanced Urothelial Cancer Who Are Ineligible for Cisplatin and Treated With First-Line Enfortumab Vedotin Alone or With Pembrolizumab.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 12, 2024
A plain language summary exploring a new treatment combination for untreated locally advanced or metastatic urothelial cancer: enfortumab vedotin plus pembrolizumab.
Journal: Future oncology (London, England)
Published: November 23, 2023
Last Updated: 09/26/2026